

INVITATION TO PERTH AND SINGAPORE INVESTOR BRIEFINGS

MELBOURNE, Australia, 4 March 2026: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, is pleased to invite investors to attend interactive briefings in Perth and Singapore.

During the briefings, CEO & Managing Director, Dr Nina Webster, will present an update on the Company's global ACTION3 Phase 3 clinical trial in focal segmental glomerulosclerosis (FSGS) kidney disease, outline the commercial partnering status of DMX-200, and discuss Dimerix' growth strategy. Investors will also be invited to ask questions throughout the sessions.

Event details

Perth - briefing for existing and potential Dimerix investors		Singapore - joint investor briefing with Dimerix and Racura Oncology (ASX: RAC)	
Date:	Monday, 16 March, 2026	Date:	Monday, 20 April, 2026
Time:	1pm for a 1:15pm start (AWST)	Time:	12:15pm for a 12:30pm start (SGT)
Location:	Steves Bar & Café 30 The Avenue, Nedlands	Location:	Singapore CBD – exact venue details TBC
Event info:	Along with Dr Webster's presentation and interactive Q+A, light refreshments will be served at the Perth briefing.	Event info:	During the Singapore briefing, Dimerix executives Dr Nina Webster and Dr Rob Shepherd (COO) will present to investors. Dr Daniel Tillett, CEO and Managing Director of Racura Oncology will also present, with both companies outlining their respective strategies and development progress. Along with the presentations, lunch will be provided. Please advise of any dietary requirements at the time of your RSVP.
Dress:	Smart casual / business	Dress:	Smart casual / business
Places are strictly limited, so please RSVP soon to secure your spot:			
RSVP:	To jane.lowe@irdepartment.com.au by Thursday, 12 March, 2026	RSVP	To: anna.cvijetic@irdepartment.com.au by Friday, 20 March, 2026

The Dimerix team looks forward to seeing all those who can make it along to the briefings.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster

Dimerix Limited

Chief Executive Officer & Managing Director

Tel: +61 1300 813 321

E: investor@dimerix.com

Jane Lowe

IR Department

Tel: +61 411 117 774

E: jane.lowe@irdepartment.com.au

Follow Dimerix on [LinkedIn](#) and [X](#)

Authorised for lodgement by Dimerix CEO & Managing Director

—END—

About Dimerix Limited

DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2045, in addition to Orphan Drug Designation granted in the United States, Europe, UK and Japan¹. For more information, please visit the company's website at www.dimerix.com and follow on [X](#) and [LinkedIn](#).

About FSGS

FSGS is a rare, serious kidney disorder characterised by progressive scarring (sclerosis) in parts of the glomeruli—the kidney's filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In the United States, more than 40,000 people are estimated to be living with FSGS, including both adults and children.² There are no therapies specifically approved for FSGS in the U.S., and disease management relies on non-specific immunosuppressive and supportive therapies. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years. Even among those who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,³ underscoring the urgent need for new, disease-modifying treatments.

About FSGS Phase 3 Study

FSGS CLINICAL STUDY

The ACTION3 Phase 3 study is a pivotal Phase 3, multi-centre, randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of a blood pressure medication known as an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients are then randomised to receive either DMX-200 (120 mg capsule, twice daily) or placebo for a 2-year treatment period.

The single Phase 3 trial in FSGS patients is designed to capture evidence of proteinuria reduction and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval.

For personal use only

Further information about the study can be found on ClinicalTrials.gov (Study Identifier: NCT05183646) or Australian New Zealand Clinical Trials Registry (ANZCTR) (Study Identifier ACTRN12622000066785).

Dimerix Forward Looking Statement

This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, including but not limited to those factors outlined in the most recent Dimerix Limited Annual Report.

References

- 1 ASX releases: 14 December 2015, 21 November 2018, 07 June 2021, 30 September 2025
- 2 Nephcure FSGS Facts (<https://nephcure.org/>)
- 3 *Front. Immunol.*, (July 2019) | <https://doi.org/10.3389/fimmu.2019.01669>